Suh KJ - Search Results

1

Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-09).

Kim M, Kim YJ, Suh KJ, Kim SH, Kim JE, Jeong J, Hong JY, Lee J, Lee SJ, Oh SY, Kim JH, Lee GW, Ahn MS, Choi W, Choi YJ, Lee T, Oum C, Kim J, Kim YS, Ahn JH. Kim M, et al. Among authors: suh kj. Cancer. 2024 Oct 18. doi: 10.1002/cncr.35609. Online ahead of print. Cancer. 2024. PMID: 39422602

2

Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.

Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS. Suh KJ, et al. Cancer Immunol Immunother. 2018 Mar;67(3):459-470. doi: 10.1007/s00262-017-2092-x. Epub 2017 Dec 4. Cancer Immunol Immunother. 2018. PMID: 29204702 Free PMC article.

3

Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.

Kim SH, Ahn S, Suh KJ, Kim YJ, Park SY, Kang E, Kim EK, Kim IA, Chae S, Choi M, Kim JH. Kim SH, et al. Among authors: suh kj. Breast Cancer Res Treat. 2020 Oct;183(3):697-704. doi: 10.1007/s10549-020-05811-2. Epub 2020 Jul 26. Breast Cancer Res Treat. 2020. PMID: 32715441

4

Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Jung EH, Jang HR, Kim SH, Suh KJ, Kim YJ, Lee JH, Chung JH, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS. Jung EH, et al. Among authors: suh kj. Thorac Cancer. 2021 Mar;12(5):619-630. doi: 10.1111/1759-7714.13834. Epub 2021 Jan 17. Thorac Cancer. 2021. PMID: 33458968 Free PMC article.

5

Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma.

Kang M, Park C, Kim SH, Yoon SW, Suh KJ, Kim YJ, Ock CY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS. Kang M, et al. Among authors: suh kj. Transl Lung Cancer Res. 2021 Feb;10(2):699-711. doi: 10.21037/tlcr-20-893. Transl Lung Cancer Res. 2021. PMID: 33718015 Free PMC article.

6

The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study.

Kim JH, Seo S, Kim JH, Koh SJ, Ahn Y, Jung KH, Ahn JH, Kim SB, Kim TW, Hong YS, Kim SY, Kim JE, Kim SW, Lee DH, Lee JC, Choi CM, Yoon S, Jeong JH, Kim HJ, Suh KJ, Kim SH, Kim YJ, Min YJ, Baek JH, Park SR. Kim JH, et al. Among authors: suh kj. Cancer Med. 2022 Feb;11(3):705-714. doi: 10.1002/cam4.4476. Epub 2021 Dec 9. Cancer Med. 2022. PMID: 34889062 Free PMC article.

7

The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.

Yang J, Kim SH, Jung EH, Kim SA, Suh KJ, Lee JY, Kim JW, Kim JW, Lee JO, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS. Yang J, et al. Among authors: suh kj. Thorac Cancer. 2023 Jan;14(1):52-60. doi: 10.1111/1759-7714.14711. Epub 2022 Nov 9. Thorac Cancer. 2023. PMID: 36351567 Free PMC article.

8

Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.

Hong S, Lee JH, Heo JY, Suh KJ, Kim SH, Kim YJ, Kim JH. Hong S, et al. Among authors: suh kj. J Cancer Res Clin Oncol. 2024 Apr 10;150(4):186. doi: 10.1007/s00432-024-05728-z. J Cancer Res Clin Oncol. 2024. PMID: 38600328 Free PMC article.

9

A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19).

Kim YJ, Kim S, Kim TM, Suh KJ, Kim M, Kim SH, Keam B, Kim DW, Lee JS, Heo DS. Kim YJ, et al. Among authors: suh kj. Lung Cancer. 2024 Aug;194:107870. doi: 10.1016/j.lungcan.2024.107870. Epub 2024 Jul 3. Lung Cancer. 2024. PMID: 38986212 Clinical Trial.

10

PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance.

Han EK, Woo JW, Suh KJ, Kim SH, Kim JH, Park SY. Han EK, et al. Among authors: suh kj. Cancer Res Treat. 2024 Apr;56(2):557-566. doi: 10.4143/crt.2023.1025. Epub 2023 Dec 12. Cancer Res Treat. 2024. PMID: 38097920 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters